Single answer
Is Atara Biotherapeutics Inc (ATRA) a buy or sell?
4starter turns market data into one clear verdict you can act on.
Create a free account to save tickers and track your signals.
Log in to turn on watchlist alerts.
Decision snapshot
Everything you need to act fast, in one glance.
What is the conclusion?
Right now our advanced algorithms say:
Do analysts agree?
We compare consensus targets with today's price.
Consensus target for Atara Biotherapeutics Inc is $15.50, which is $10.22 (193.56%) above the current price today's price.
Low target: $6.00 | High target: $25.00
Latest analyst updates
Recent rating and price target changes for this stock.
Company snapshot
A quick overview of the business and its public profile.
Atara Biotherapeutics Inc an offtheshelf Tcell immunotherapy company develops treatments for patients with cancer autoimmune and viral diseases in the United States It is developing tabelecleucel a Tcell immunotherapy that is Phase 3 clinical trials for the treatment of epsteinbarr virus EBV driven posttransplant lymphoproliferative disease as well as hematologic and solid tumors including nasopharyngeal carcinoma The company is also developing nextgeneration CAR T immunotherapies for patients with hematologic malignancies and solid tumors including ATA2271 and ATA3271 for mesothelin and ATA2431 and ATA3219 for Bcell malignancies as well as ATA188 for the treatment of multiple sclerosis In addition it develops ATA368 program for patients with human papillomavirus associated cancers Atara Biotherapeutics Inc has a license agreement with Memorial Sloan Kettering Cancer Center license and research and development collaboration agreement with QIMR Berghofer Medical Research Institute and strategic collaboration with H Lee Moffitt Cancer Center as well as Bayer AG for mesothelintargeted CAR Tcell therapies for solid tumors The company was incorporated in 2012 and is headquartered in South San Francisco California
Website: https://www.atarabio.com
Rates and inflation backdrop
US inflation for January 2026 was 0.17%. Over the last 12 months, inflation is 2.83%. The 10-year yield is 4.04 and is down -0.110 over the last 30 days.
Inflation sensitivity
Debt ratio: 1.94. Cash flow to debt ratio: -1.19. Net profit margin: 15.40%. Inflation risk score: medium (0.70/1).
Dividend history check
We cannot find any recorded dividends paid in our systems.
Trading liquidity
Yes, the average daily trading liquidity for Atara Biotherapeutics Inc is $1.7M. You should therefore be able to get in and out of your positions relatively fast.
10-year return check
On Atara Biotherapeutics Inc, 2016-02-26 had a stock price of $17.15. If you invested back then, your return now would be a loss of $12.09 per share or 70.50%.
Why this answer
We combine price momentum, volatility, and trend signals to simplify the decision to one word.
Signal engine scans price, trend, and momentum indicators.
Targets and sentiment are checked against the live quote.
We keep the output simple: buy, sell, or hold.
Analyst consensus
How Wall Street targets compare to today's price.